---
pmid: '34686346'
title: Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT
  signaling and promotes prostate tumorigenesis.
authors:
- Duan S
- Moro L
- Qu R
- Simoneschi D
- Cho H
- Jiang S
- Zhao H
- Chang Q
- de Stanchina E
- Arbini AA
- Pagano M
journal: Cell Rep
year: '2021'
full_text_available: false
pmcid: PMC8577224
doi: 10.1016/j.celrep.2021.109870
---

# Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis.
**Authors:** Duan S, Moro L, Qu R, Simoneschi D, Cho H, Jiang S, Zhao H, Chang Q, de Stanchina E, Arbini AA, Pagano M
**Journal:** Cell Rep (2021)
**DOI:** [10.1016/j.celrep.2021.109870](https://doi.org/10.1016/j.celrep.2021.109870)
**PMC:** [PMC8577224](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577224/)

## Abstract

1. Cell Rep. 2021 Oct 19;37(3):109870. doi: 10.1016/j.celrep.2021.109870.

Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT 
signaling and promotes prostate tumorigenesis.

Duan S(1), Moro L(1), Qu R(1), Simoneschi D(1), Cho H(1), Jiang S(1), Zhao H(2), 
Chang Q(2), de Stanchina E(2), Arbini AA(3), Pagano M(4).

Author information:
(1)Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of 
Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura 
and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The 
Alexandria Center for Life Science, New York, NY 10016, USA.
(2)Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, 
New York, New York 10065, USA.
(3)Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, 
The Alexandria Center for Life Science, New York, NY 10016, USA; Department of 
Pathology, NYU Grossman School of Medicine, The Alexandria Center for Life 
Science, New York, NY 10016, USA.
(4)Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of 
Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura 
and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The 
Alexandria Center for Life Science, New York, NY 10016, USA; Howard Hughes 
Medical Institute, NYU Grossman School of Medicine, The Alexandria Center for 
Life Science, New York, NY 10016, USA. Electronic address: 
michele.pagano@nyumc.org.

FBXO31 is the substrate receptor of one of many CUL1-RING ubiquitin ligase 
(CRL1) complexes. Here, we show that low FBXO31 mRNA levels are associated with 
high pre-operative prostate-specific antigen (PSA) levels and Gleason grade in 
human prostate cancer. Mechanistically, the ubiquitin ligase CRL1FBXO31 promotes 
the ubiquitylation-mediated degradation of DUSP6, a dual specificity phosphatase 
that dephosphorylates and inactivates the extracellular-signal-regulated 
kinase-1 and -2 (ERK1/2). Depletion of FBXO31 stabilizes DUSP6, suppresses ERK 
signaling, and activates the PI3K-AKT signaling cascade. Moreover, deletion of 
FBXO31 promotes tumor development in a mouse orthotopic model of prostate 
cancer. Treatment with BCI, a small molecule inhibitor of DUSP6, suppresses AKT 
activation and prevents tumor formation, suggesting that the FBXO31 tumor 
suppressor activity is dependent on DUSP6. Taken together, our studies highlight 
the relevance of the FBXO31-DUSP6 axis in the regulation of ERK- and 
PI3K-AKT-mediated signaling pathways, as well as its therapeutic potential in 
prostate cancer.

Copyright Â© 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

DOI: 10.1016/j.celrep.2021.109870
PMCID: PMC8577224
PMID: 34686346 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests M.P. is a cofounder of 
Coho Therapeutics. He is also a consultant for, a member of the scientific 
advisory board of and has financial interests in Coho Therapeutics, CullGen, 
Kymera Therapeutics, Santi Therapeutics, and SEED Therapeutics.
